Frontiers in Medical Science Research, 2024, 6(3); doi: 10.25236/FMSR.2024.060304.
Sun Jianhua1, Li Zengyan2
1Baotou Medical College, Inner Mongolia, Baotou, 014040, China
2Department of Nephrology, the First Affiliated Hospital of Baotou Medical College, Inner Mongolia, Baotou, 014040, China
The rat model of IgA nephropathy induced by immunogen plus endotoxin was established, and the drug dose and method improved on the basis of IgA nephropathy model were carried out to establish a more suitable rat model of clinical IgA nephropathy. BAFF and Gd-IgA 1 expression were measured from the serum and kidney tissues of IgA nephropathy rats. SD males, 24 mice with 0.18-0.2Kg body mass, were randomly divided into control and model groups. Model: immunized bovine serum albumin (Bovine Serum Albumin V, BSA) dissolved at 150g / L, 600mg / Kg the next day, premixed with castor oil and carbon tetracloride, concentration 3:1; subcutaneous 0.4ml / only once a week for 12 weeks. A 0.05mg dose of lipopolysaccharide (Lipopolysaccharides, LPS) was administered in the tail vein at weeks 6,8, and 10, and the control group in saline. At the end of week 12 of intervention, blood was collected from the abdominal aorta for 24-h proteinuria (24h pro), serum creatinine (SCr) and urea nitrogen (BUN). HE, PAS pathological staining, electron microscopy and light microscopy, and BLyS and Gd-IgA 1 expression in serum and kidney tissues using ELISA experiments. In the model group, the content of proteinuria, Cre and BUN increased significantly at 24h, and the pathological staining results showed obvious morphological changes, and the area of enhanced fluorescence positive by pathological immunofluorescence staining increased. BLyS and Gd-IgA 1 expression were higher in serum and kidney tissues than in the blank control group. The modified molding method of IgA nephropathy had good results, and the pathological and clinical indicators were close to clinical IgA nephropathy.
Immunization, BAFF/Gd-IgA1, IgA Nephropathy (IgAN)
Sun Jianhua, Li Zengyan. Immunization-induced Establishment and Serum Expression of BAFF/Gd-IgA1 in IgAN Rats. Frontiers in Medical Science Research (2024), Vol. 6, Issue 3: 21-25. https://doi.org/10.25236/FMSR.2024.060304.
[1] Donadio, J.V. and J.P. Grande, IgA Nephropathy. New England Journal of Medicine, 2002. 347(10): p. 738-748.
[2] Heine, G., Sester, U., & Kohler, H. (2023). IgA nephropathy. Journal of Nephrology. doi: 1533-4406 (Electronic). p.160-165.
[3] Petrou, D., et al., IgA Nephropathy: Current Treatment and New Insights. Antibodies, 2023. 12(2).
[4] Hassler, J.R. IgA nephropathy: A brief review. Nephrology Journal. 2023. doi: 0740-2570 (Print). Source: PubMed.
[5] Gross, J.A., et al., TACI-Ig Neutralizes Molecules Critical for B Cell Development and Autoimmune Disease. Immunity, 2001. 15(2): p. 289-302.
[6] Suzuki, H., Biomarkers for IgA nephropathy on the basis of multi-hit pathogenesis. Clinical and Experimental Nephrology, 2018. 23(1): p. 26-31.
[7] Okazaki, K., et al., Development of a Model of Early-Onset IgA Nephropathy. Journal of the American Society of Nephrology, 2012. 23(8): p. 1364-1374.
[8] Ma, S., et al., Effects of modified Huangqi Chifeng decoction on the IL-17 signaling pathway in an IgA nephropathy rat model. Journal of Ethnopharmacology, 2023. 307(1872-7573 (Electronic)).
[9] Sun Hongxu, Lu Yan, and Wang Yi, the establishment and evaluation of the immunogenic IgAN rat model. Chinese Journal of Integrated Chinese and Western Medicine, 2019.20 (01): p. 8-10.
[10] Berthoux, F.C., H. Mohey, and A. Afiani, Natural History of Primary IgA Nephropathy. Seminars in Nephrology, 2008. 28(1): p. 4-9.
[11] Xu Lili and Wang Weiming, the progress in the treatment of IgA nephropathy. Journal of Clinical Nephrology, 2023.23 (01): p. 70-74.